Nutritional products maker USANA's prelim Q3 sales miss estimates

USANA Health Sciences

09/10/2025 21:21

Overview

USANA preliminary Q3 net sales of $214 mln missed analyst expectations

Preliminary adjusted EPS for Q3 was negative, reflecting sales and productivity challenges

Company faced high effective tax rate impacting Q3 profitability

Outlook

USANA expects full-year sales at the lower end of previous guidance

USANA anticipates future lower tax rate due to cost alignment efforts

Result Drivers

COMPENSATION PLAN TRANSITION - Co attributes softer sales and productivity to the rollout of an enhanced Brand Partner compensation plan

HIYA SALES - Hiya's lower than anticipated customer acquisition rates led to softer sales in a seasonally strong quarter

HIGH TAX RATE - Co faced a significant increase in the effective income tax rate, impacting Q3 profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Prelim Q3 Sales
Miss
$214 mln
$224.10 mln (1 Analyst)
Prelim Q3 EPS
-$0.36


Analyst Coverage

Wall Street's median 12-month price target for USANA Health Sciences Inc is $61.00, about 56.5% above its October 8 closing price of $26.51

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw72nDPHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)